Raymond Francis Anton, Jr, MD

Dr. Lauren Carter is a licensed clinical psychologist. She received her Ph.D. in clinical psychology from Florida State University. Dr. Carter completed her predoctoral internship at the Charleston Consortium Clinical Psychology Internship Program (MUSC and Ralph Johnson VA) and her postdoctoral fellowship specializing in behavioral medicine at MUSC. Following her fellowship in behavioral medicine, Dr. Carter joined the faculty at MUSC in the Department of Psychiatry and Behavioral Sciences, Division of Bio-Behavioral Medicine. Dr. Carter's clinical practice specializes in assessment and intervention that is focused on optimizing quality of life in patients who are experiencing a variety of medical and psychiatric conditions. She currently sees patients in the Institute of Psychiatry and Women's Health at Resolute Way, primarily working with the following populations: bariatric (pre-/post- surgery), eating and weight disorders, solid organ transplant (pre-/post- transplant), chronic pain, women's health, and co-occurring substance use disorders within these populations. ,In addition to patient care, Dr. Carter is currently active in clinical research and training. She serves as a supervisor in the Behavioral Medicine Clinic and the Women's Reproductive Behavioral Health Clinic for the Charleston Consortium Clinical Psychology Internship Program. Her research interests focus broadly on eating and weight disorders, exercise, quality of life, and behavioral medicine.

In 1995, Dr. Mark George, a South Carolina native, returned to Charleston and built a campus-wide research brain imaging division and the brain stimulation laboratory in the Department of Psychiatry. As an undergraduate student in philosophy at Davidson College, Dr. George began studying the relationship between mind and brain, or brain/behavior relationships. He has continued this interest throughout his career with a focus on using brain imaging and brain stimulation to understand depression and devise new treatments. He received his medical degree from MUSC in 1985, where he continued with dual residencies in both neurology and psychiatry. He is board certified in both areas.Following his residency training he worked for one year (from 1990 to 1991) at the Institute of Neurology, Queen Square, London, England. He then moved to Washington, DC, working in the Intramural National Institute of Mental Health (NIMH). He was one of the first to use functional brain imaging during normal emotions as well as in depression and mania. He has grown the science of brain stimulation, both in terms of how the treatments work in the brain, and in critically evaluating their therapeutic applications, especially in treating depression. He may be unique in being the only living neuroscientist with two FDA approved treatments that stem from their work. Transcranial magnetic stimulation (TMS) was FDA approved for treating depression in October, 2008. In June 1998 at MUSC, he also pioneered another new treatment for resistant depression, vagus nerve stimulation (VNS). This was FDA approved in 2006. Dr. George is a world expert in brain stimulation, and depression, and is the editor-in-chief of a journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has been continuously funded by NIH and other funding agencies since his fellowships. He has received numerous national and international awards. In 2009 U.S. News and World Report named him one of 14 ‘medical pioneers who are not holding back’. He has published over 400 scientific articles or book chapters, and has written or edited six books.

Dr. Jennifer Dahne received her Ph.D. in Clinical Psychology from the University of Maryland, College Park in 2016. She completed her predoctoral internship at the Medical University of South Carolina/Ralph H. Johnson VA Medical Center and her postdoctoral fellowship via MUSC's National Institute on Drug Abuse (NIDA) T32 training program. Dr. Dahne subsequently joined the MUSC faculty in 2018 and she is currently an Associate Professor, affiliated both with the Addiction Sciences Division of the Department of Psychiatry and with the Hollings Cancer Center, Cancer Control Program. The overarching goal of Dr. Dahne's research program is to significantly reduce the public health impact of tobacco use, with a specific focus on cigarette smoking among vulnerable populations (e.g. socioeconomically disadvantaged adults, individuals with additional physical and mental health comorbidities). The majority of Dr. Dahne's work centers around development and evaluation of technology-based remote interventions for the treatment of smoking cessation and common comorbidities (e.g. depression). Dr. Dahne also currently serves as Co-Director of MUSC's Remote & Virtual Trials Program and has interests in developing methods to improve the feasibility and rigor of remote trials. Dr. Dahne is a current NIDA K23 recipient and is also PI of a NIDA-funded R41, a National Cancer Institute-funded R21, and a National Institute of Mental Health-funded R42. She is also an active collaborator on several NIH-funded projects focused on smoking cessation and telehealth intervention delivery.